

Spread of CTX-M-15 Extended Spectrum β -lactamases Encoding Genes Among Enterobacteriaceae in the Middle Eastern Region

Maysa Baroud¹, George F. Araj² and Ghassan M. Matar^{1*3}

Abstract

The CTX-M type enzymes have become the most prevalent extended spectrum β -lactamases (ESBLs) worldwide. Among the CTX-M type enzymes, CTX-M-15 is the most widespread and has been reported from all continents. It has been recovered from different *Enterobacteriaceae* and has been isolated from both community and hospital acquired infections. This review primarily highlights the prevalence of CTX-M-15 in addition to other ESBLs in the Middle East. Detection of any type of ESBL is of importance in therapeutic treatment.

Keywords: CTX-M-15, ESBL, Middle East, antimicrobial resistance, Enterobacteriaceae.

- 1 Experimental Pathology, Immunology and Microbiology.
- 2 Pathology and Laboratory Medicine, Faculty of Medicine, American University of Beirut, Beirut, Lebanon.
- 3 Faculty of Medicine, American University of Beirut Beirut, Lebanon

* **Correspondence:**
Ghassan M. Matar, Ph.D.

E-mail: gmatar@aub.edu.lb

Tel: +961-1-350000/6128

Introduction

As is the case for many antimicrobial agents, over-use of the extended spectrum oxyimino-cephalosporins, which are agents developed to treat organisms producing β -lactamases, resulted in the production of enzymes capable of hydrolyzing these agents. In 1983, the first extended spectrum β lactamase, an SHV β -lactamase derivate, was isolated in Germany from a *Klebsiella* isolate (1,2). Since then, the family of ESBLs has grown to include enzymes belonging to Ambler Classes A, including many derivatives of plasmid mediated TEM and SHV penicillinases, and a small number of Class D OXA-type β -lactamases (2,3). A third type of Class A ESBLs, the cefotaximase, or CTX-M enzyme, was first identified from an *Escherichia coli* isolate in Germany in 1990 (4). Unlike other ESBLs, this enzyme hydrolyzed cefotaxime more efficiently than ceftazidime, and in general, CTX-M enzymes tend to confer resistance to cefotaxime but not to ceftazidime (4,5).

Outbreaks of organisms producing CTX-M type ESBLs were reported from around the world as early as the 1990s, however, with a few exceptions, organisms expressing these enzymes were not identified in the Middle East till earlier this decade (2,5,6,7). Over the past ten years, the CTX-M enzymes have become the most prevalent ESBLs among multidrug resistant organisms worldwide, especially in certain countries in Europe and South America (6,8,9,10). As for the Middle East, there is little data on the prevalence and distribution of these enzymes.

These enzymes are of special importance because they have been isolated from both hospital and community-acquired isolates, particularly *Escherichia coli* isolates causing urinary tract infections; and, also because of their clonal, plasmid-mediated nature (6,7,8). The majority of CTX-M type enzymes are associated with the insertion sequence *ISEcp1* (9,11).

A major enzyme among the CTX-M ESBLs is CTX-M-15, an enzyme that has been associated with epidemic and mosaic plasmids, and that may play a role in conferring carbapenem resistance when found in isolates showing outer membrane impermeabilities (3,9,12,13). Unlike other CTX-M enzymes, CTX-M-15 efficiently hydrolyzes both cefotaxime and ceftazidime (14). In addition CTX-M-15, encoded by the *bla*_{CTX-M-15} gene, is sometimes associated with other ESBLs encoding genes, such as *bla*_{TEM} and *bla*_{SHV} derivatives and *bla*_{OXA-1} as well as genes encoding for resistance to other antimicrobial agents, such as the *qnrA* and *qnrB* genes conferring resistance to fluoroquinolones, and *aac(6)-Ib-cr*, conferring resistance to aminoglycosides and fluoroquinolones (15,16,17,18,19). It was first detected in an *E. coli* isolate in India in 2001, but since then, it has become the most disseminated ESBL worldwide, mainly as a single clone ST131 O25:H4 (14,20). It is the predominant CTX-M enzyme in Europe, and in India, which may be considered a major reservoir for *E. coli* isolates harboring the *bla*_{CTX-M-15} gene (6,20,21,22). It has also been identified in *E. coli* isolates from North and South America, Asia, Australia, Africa and the Middle East (10,23-28).

Distribution of *bla*_{CTX-M-15} in the Middle East

Among the Middle Eastern countries, CTX-M-15 is most widespread and is the predominant ESBL in Egypt, Kuwait, Lebanon, and the United Arab Emirates; as for other countries in the region, distribution and prevalence varies or has not been reported yet (28-31).

Egypt

High rates of ESBL production have been reported for Egypt since 2003, however, the presence of *bla*_{CTX-M-15} was not reported until 2006, in a study conducted by Al-Agamy et al (29,32,33). Al-Agamy et al found that 25 of 28 ESBL producing *E. coli* isolates were carriers of CTX-M type enzymes, and that of these isolates, 13 harbored *bla*_{CTX-M-15} (29). At the time, there was no information available on the spread of CTX-M enzymes in Egypt (29). Since then, a more thorough study conducted by Fam et al identified 74 isolates producing *bla*_{CTX-M-15}, constituting all ESBL producers that were available for molecular study (34).

Iran

Feizabadi et al reported in 2006 a high prevalence of ESBL production among *K. pneumoniae* isolates collected at two teaching hospitals in Tehran, Iran (35). A similar study conducted in 2008 by Mehrgan et al reported that among the high number of ESBL producing *E. coli* isolates identified, some showed an antimicrobial resistance profile suggestive of the presence of a CTX-M type enzyme, but molecular data was lacking (36).

In 2009, Ramazanzadeh et al studied the spread of ESBLs in Intensive Care Units in two major hospitals in Sanandaj and found that the most prevalent ESBL belonged to the CTX-M family, but the types of CTX-M enzymes present were not determined (37). Following in 2010, Feizabadi et al reported the presence of the *bla*_{CTX-M-15} gene in a high number of ESBL producing *K. pneumoniae* isolates among those tested (38). Later studies conducted by Feizabadi et al showed an increase in the CTX-M phenotype among ESBL producing *K. pneumoniae* isolates collected from hospitalized patients (39). In Iran, CTX-M-15 has also been identified among different *Salmonella enterica* serovars and among non-typhoidal *Salmonella* strains (40,41).

Iraq

ESBL production has been reported in Iraq, however, molecular data is scarce in the country (42). Reports of Iraqi isolates producing the CTX-M-15 enzyme come from studies conducted in France and Germany (43,44). In both cases, the isolates were transferred to these respective countries by patients from Iraq (43,44). In France, the CTX-M-15 enzyme was associated with *bla*_{NDM-1} production in a *K. pneumoniae* isolate (43). In Germany, the CTX-M-15 enzyme was isolated from a *Salmonella enterica* serovar Typhi (44). This data suggests that CTX-M-15 may be prevalent in Iraq.

Kuwait

Two studies from 2008 identifying the *E. coli* ST131 clone producing CTX-M-15 in a number of countries worldwide also identified this clone in Kuwait (45,46). Also in 2008, Rotimi et al reported for the first time in Kuwait, and in the gulf region, an outbreak of *Salmonella* spp producing CTX-M-15 (47). In 2009, Ensor et al tried to identify the prevalence of CTX-M enzymes in Kuwait by randomly selecting 43 ESBL producing *E. coli* and *K. pneumoniae* isolates collected at the Mubarak hospital and found that among these isolates, CTX-M-15 was the predominant enzyme (30). In 2010 and 2011, CTX-M-15 was identified from *Klebsiella pneumoniae* isolates in a number of studies, and a CTX-M-15-like enzyme clone was identified from an outbreak occurring in a neonatal intensive care unit at Al Jahra hospital (48,49). The *K. pneumoniae* isolate identified at the Al Jahra hospital also carried *bla*_{TEM-1} and *bla*_{SHV-112} genes (49).

In 2010, Al Hashem et al attempted to investigate the extent and distribution of *bla*_{CTX-M} genes among *E. coli* isolates from all government hospitals in Kuwait. Isolates were collected from eight major hospitals in Kuwait and 136 ESBL producers were identified. The most prevalent enzyme among the ESBL producers, with a prevalence of 84.1%, was CTX-M-15, suggesting that Kuwait may be an important source for CTX-M-15 producing *E. coli* isolates (50).

Lebanon

In Lebanon, there is a countrywide dissemination of the *bla*_{CTX-M-15} gene (28). CTX-M-15 has been identified in many members of the *Enterobacteriaceae* from both community and hospital acquired infections (28,51,52,53). In a nationwide study conducted in 2005 that included six tertiary care centers in Lebanon, Moubareck et al identified CTX-M-15 from *E. coli*, *Klebsiella pneumoniae*, and *Enterobacter cloacae* isolates (28). That same year, Moubareck et al identified the first *Salmonella enterica* serovar Typhimurium isolate producing CTX-M-15 in the country, reporting for the first time in Lebanon an ESBL producing *Salmonella* isolate (53). Subsequently, Kanj et al reported a high prevalence of CTX-M-15 production in *E. coli* and *K. pneumoniae* isolates from a tertiary care center in Lebanon and Matar et al reported CTX-M-15 from two *Salmonella enterica* serovar Typhimurium isolates and three *Shigella sonnei* isolates, making CTX-M-15 the predominant ESBL identified in the country (51,52, 54,55).

Oman

Studies conducted in Oman on isolates collected from pediatric patients, intensive care unit and other hospitalized patients and from outpatient clinics suggest an increasing prevalence of ESBL producers, however, these studies did not attempt to identify the types of ESBL genes present (56,57,58). In a review on susceptibilities of common bacterial isolates collected from the Royal Hospital in Oman, resistance to third generation cephalosporins varied among the *Enterobacteriaceae*, and, as

mentioned by the authors, was possibly due to CTX-M type enzymes, which had been detected at the center previously (59). The only report of an isolate producing CTX-M-15 coming from Oman is from a *K. pneumoniae* isolate also harboring *bla*_{NDM-1} (60).

Saudi Arabia

Al Agamy et al identified the first CTX-M enzymes from Saudi Arabia in 2009 in a study they conducted to determine the prevalence of ESBLs among *K. pneumoniae* isolates in Riyadh (61). Prevalent among these enzymes were *bla*_{CTX-M-15} like genes belonging to the CTX-M-1 group (61). Furthermore, Bindayna et al reported in 2010 that the most prevalent ESBL among 100 isolates collected in Dhahran was CTX-M, however, in this study the specific type of CTX-M enzyme present was not determined (62). In 2011, Tawfik et al reported a high prevalence of CTX-M-15 among 110 ESBL producing clinical *K. pneumoniae* isolates collected in Al-Qassim (63).

Turkey

In 2003, Lartigue et al reported the first clinical isolate, a *Klebsiella pneumoniae*, producing CTX-M-15 in Turkey (64). In 2007, Yildirim et al reported a *Klebsiella pneumoniae* isolate that produced *bla*_{CTX-M-15} as well as a carbapenemase (65). Following in 2008, a study conducted at a university hospital in Istanbul by Gonullu et al revealed a high prevalence of CTX-M-15 among *E. coli* isolates recovered from inpatients and outpatients treated at the center (66). Similarly, between 2008 and 2010, studies to determine the prevalence of CTX-M-15 production in *E. coli* isolates from community acquired infections reported that the prevalence of CTX-M-15 was quite high among those isolates producing ESBLs (67,68,69).

United Arab Emirates

In a first report of the production of CTX-M-type enzymes in the Arabian Peninsula, five entero-aggregative *E. coli* isolates from the United Arab Emirates were found to harbor *bla*_{CTX-M-15} and *bla*_{TEM-1} (31). CTX-M-15 was then identified in a single *Salmonella* group C isolate in the 2008 study conducted by Rotimi et al mentioned previously (47). In 2011, in a study collecting ESBL producing isolates from hospitalized patients in three hospitals across the UAE, the majority of the isolates among those identified as ESBL producers harbored *bla*_{CTX-M-15} (70).

Others

In the Gaza Strip, Jordan, and Bahrain, resistance data suggests the production of extended spectrum β -lactamases but to date no studies have attempted to identify and characterize the ge-

netic determinants causing this ESBL phenotype (33,71,72). In one study from Jordan, Shehabi et al observed a high rate of *Klebsiella pneumoniae* isolates resistant to extended spectrum cephalosporins among ICU patients, suggesting that these isolates were potentially ESBL producers; extended spectrum cephalosporin resistance was also observed among *E. coli* and *Enterobacter* spp isolates, but at a lower rate (74). Though there have been no reports of CTX-M-15 throughout the rest of Palestine, other CTX-M enzymes, especially CTX-M-2, have been identified from *E. coli* isolates (75). No data has been published on ESBLs for Yemen, Qatar and Syria.

Conclusion

Data from the Middle East shows that CTX-M-15 is prevalent in more than one country, and that the encoding gene is many times associated with other resistance encoding genes, including other ESBLs (31,38,51). This is not surprising as in many countries in the Middle East antimicrobials can be purchased without a prescription and are commonly misused, possibly resulting in the selection of antimicrobial resistant strains (29,36,50). In Kuwait, a number of studies attributed part of the high prevalence of CTX-M-15 to a large population of non-nationals; this could also be the case for other countries in the gulf region, where many non-nationals also live (30,50).

Since the ST131 clone carrying CTX-M-15 was identified in Kuwait, Multi-Locus Sequence Typing may shed light on whether the same clone is prevalent in other countries in the Middle East (45,46). Similar to reports from other countries, CTX-M-15 was identified from both hospital and community acquired infections and in a number of members of the Enterobacteriaceae, including *E. coli*, *K. pneumoniae*, and *Salmonella* spp (6,9). In many instances, the *bla*_{CTX-M-15} gene was found to be encoded by an *ISEcp1* insertion sequence, as reported elsewhere (31,47, 51-53,64).

Finally, though some countries in the Middle East have reported molecular data on the types of ESBLs present, many countries fail to routinely identify ESBLs and lack data on the prevalence of isolates producing these enzymes at the national level. The high prevalence of ESBL production among all types of *Enterobacteriaceae* reported from a number of countries implies that there is an urgent need for regular screening for extended spectrum β -lactamases production, in order to identify such genes as CTX-M-15, but also others. Determining the presence of an ESBL and then identifying its type is important for prescribing proper antimicrobial treatment and for avoiding therapeutic failure or an unwanted clinical outcome (37,75,76,77).

References

- Kliebe C, Nies BA, Meyer JF, Tolxdorff-Neutzling RM, Wiedemann B: Evolution of plasmid-coded resistance to broad-spectrum cephalosporins. *Antimicrob Agents Chemother* 1985, 28(2): 302-307
- Bradford PA: Extended-Spectrum β -Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance Threat. *Clin Microbiol Rev* 2001, 14(4): 933-951
- Livermore DM, Woodford N: The β -lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. *Trends Microbiol* 2006, 14(9): 412-420
- Bauemfeind A, Grimm H, Schweighart S: A New Plasmidic Cefotaximase in a Clinical Isolate of Escherichia coli. *Infection* 1990, 18(5): 294-298
- Paterson DL, Bonomo RA: Extended-Spectrum β -Lactamases: a Clinical Update. *Clin Microbiol Rev* 2005, 18(4): 657-686
- Livermore D, Cantón R, Gniadkowski M, Nordmann P, Rossolini GM, Arlet G, Ayala J, Coque TM, Kern-Zdanowicz I, Luzzaro F, Poirel L, Woodford N: CTX-M: changing the face of ESBLs in Europe. *J Antimicrob Chemother* 2006, 59(2): 165-174
- Cantón R, Novais A, Valverde A, Machado E, Peixe L, Baquero F, Coque TM: Prevalence and spread of extended-spectrum β -lactamase-producing Enterobacteriaceae in Europe. *Eur J Clin Microbiol Infect Dis* 2008, Suppl. 1: 144-153
- Pitout JDD, Laupland KB: Extended-spectrum β -lactamase-producing Enterobacteriaceae: an emerging public-health concern. *Lancet Infect Dis* 2008, 8(3): 159-166
- Cantón R, Coque TM: The CTX-M β -lactamase pandemic. *Curr Opin Microbiol* 2006, 9(5): 466-475
- Villegas MV, Kattan JN, Quinteros MG, Casellas JM: Prevalence of extended-spectrum β -lactamases in South America. *Clin Microbiol Infect* 2008, 14(Suppl. s1): 154-158
- Poirel L, Lartigue MF, Decousser JW, Nordmann P: ISEcp1B-Mediated Transposition of blaCTX-M in Escherichia coli. *Antimicrob Agents Chemother* 2005, 49(1): 447-550
- Baroud M, Araj GF, Wakim R, Kanj S, Kanafani Z, Khairallah M, Sabra A, Shehab M, Dbaibo G, Matar GM: Underlying Mechanisms of Carbapenem Resistance in ESBL-Producing Enterobacteriaceae at a Tertiary Care Center in Lebanon. 51st Intersci Conf Antimicrob Agents Chemother. abstr. C1-1108
- Gröbner S, Linke D, Schutz W, Fladerer C, Madlung J, Autenrieth IB, Witte W, Pfeifer Y: Emergence of carbapenem-non-susceptible extended-spectrum β -lactamase-producing Klebsiella pneumoniae isolates at the university hospital of Tübingen, Germany. *J Med Microbiol* 2009, 58(Pt 7): 912-922
- Karim A, Poirel L, Nagarajan S, Nordmann P: Plasmid-mediated extended-spectrum β -lactamase (CTX-M-3 like) from India and gene association with insertion sequence ISEcp1. *FEMS Microbiol Lett* 2001, 201(2): 237-241
- Nordmann P, Poirel L: Emergence of plasmid-mediated resistance to quinolones in Enterobacteriaceae. *J Antimicrob Chemother* 2005, 56(3): 463-469
- Jacoby GA, Walsh KE, Mills DM, Walker VJ, Oh H, Robicsek A, Hooper DC: qnrB, Another Plasmid-Mediated Gene for Quinolone Resistance. *Antimicrob Agents Chemother* 2006, 50(4): 1178-1182
- Machado E, Coque TM, Cantón R, Baquero F, Sousa JC, Peixe L: Dissemination in Portugal of CTX-M-15-, OXA-1-, and TEM-1-Producing Enterobacteriaceae Strains Containing the aac(6')-Ib-cr Gene, Which Encodes an Aminoglycoside- and Fluoroquinolone-Modifying Enzyme. *Antimicrob Agents Chemother* 2006, 50(9): 3220-3221
- Karisik E, Ellington MJ, Pike R, Ward ME, Fagan EJ, Livermore DM, Woodford N: Molecular characterization of plasmids from CTX-M-15-producing Escherichia coli strains responsible for outbreaks in the United Kingdom. *Clin Microbiol Infect* 2005, 11(Suppl. 2): P471
- Harajly M, Khairallah MT, Corkill JE, Araj GF, Matar GM: Frequency of conjugative transfer of plasmid-encoded ISEcp1 - blaCTX-M-15 and aac(6')-Ib-cr genes in Enterobacteriaceae at a tertiary care center in Lebanon - role of transferases. *Ann Clin Microbiol Antimicrob* 2010, 9(19)
- Peirano G, Pitout JDD: Molecular epidemiology of Escherichia coli producing CTX-M β -lactamases: the worldwide emergence of clone ST131 O25:H4. *Int J Antimicrob Agents* 2010, 35(4): 316-321
- Ensor VM, Shahid M, Evans JT, Hawkey PM: Occurrence, prevalence and genetic environment of CTX-M β -lactamases in Enterobacteriaceae from Indian hospitals. *J Antimicrob Chemother* 2006, 58(6): 1260-1263
- Varsha G, Datta P: Extended-spectrum β -lactamases (ESBL) in community isolates from North India: frequency and predisposing factors. *Int J Infect Dis* 2007, 11(1): 88-89
- Lewis JS, Herrera M, Wickes B, Patterson JE, Jorgensen JH: First Report of the Emergence of CTX-M-Type Extended-Spectrum β -Lactamases (ESBLs) as the Predominant ESBL Isolated in a U.S. Health Care System. *Antimicrob Agents Chemother* 2001, 51(11): 4015-4021
- Mulvey MR, Bryce E, Boyd D, Ofner-Agostini M, Christianson S, Simor AE, Paton S, Canadian Hospital Epidemiology Committee, Canadian Nosocomial Infection Surveillance Program, Health Canada: Ambler Class A Extended-Spectrum β -Lactamase-Producing Escherichia coli and Klebsiella spp. in Canadian Hospitals. *Antimicrob Agents Chemother* 2004, 48(4): 1204-1214
- Hawkey PM: Prevalence and clonality of extended-spectrum β -lactamases in Asia. *Clin Microbiol Infect* 2008, 14(Suppl. s1): 159-165
- Zong Z, Partridge SR, Thomas L, Iredell JR: Dominance of blaCTX-M within an Australian Extended-Spectrum β -Lactamase Gene Pool. *Antimicrob Agents Chemother* 2008, 52(11): 4198-4202
- Mamlouk K, Boutiba-Ben Boubaker I, Gautier V, Vimont S, Picard B, Ben Redjeb S, Arlet G: Emergence and Outbreaks of CTX-M β -Lactamase-Producing Escherichia coli and Klebsiella pneumoniae Strains in a Tunisian Hospital. *J Clin Microbiol* 2006, 44(11): 4049-4056
- Moubareck C, Daoud Z, Hakimé NI, Hamze M, Mangeney N, Matta H, Mokhbat JE, Rohban R, Sarkis DK, Doucet-Populaire F: Countrywide Spread of Community- and Hospital-Acquired Extended-Spectrum β -Lactamase (CTX-M-15)-Producing Enterobacteriaceae in Lebanon. *J Clin Microbiol* 2005, 43(7): 3309-3313
- Al-Agamy MHM, Ashour MSE, Wiegand I: First description of CTX-M β -lactamase-producing clinical Escherichia coli isolates from Egypt. *Int J Antimicrob Agents* 2006, 27(6): 545-548
- Ensor VM, Jamal W, Rotimic VO, Evans JT, Hawkey PM: Predominance of CTX-M-15 extended spectrum β -lactamases in diverse Escherichia coli and Klebsiella pneumoniae from hospital and community patients in Kuwait. *Int J Antimicrob Agents* 2009, 33(5): 487-489
- Sonnevend A, Al Dhaheri K, Mag T, Herpay M, Kolodziejek J, Nowotny N, Usmani A, Sheikh FA, Pál A: CTX-M-15-producing

- multidrug-resistant enteroaggregative *Escherichia coli* in the United Arab Emirates. *Clin Microbiol Infect* 2006, 12(6): 582-585
32. El Kholly A, Baseem H, Hall GS, Procop GW, Longworth DL: Antimicrobial resistance in Cairo, Egypt 1999–2000: a survey of five hospitals. *J Antimicrob Chemother* 2003, 51(3): 625–630
 33. Borg MA, van de Sande-Bruinsma N, Scicluna E, de Kraker M, Tiemersma E, Monen J, Grundmann H, ARMed Project Members and Collaborators: Antimicrobial resistance in invasive strains of *Escherichia coli* from southern and eastern Mediterranean laboratories. *Clin Microbiol Infect* 2008, 14(8): 789–796
 34. Fam N, Leflon-Guibout V, Fouad S, Aboul-Fadl L, Marcon E, Desouky D, El-Defrawy I, Abou-Aitta A, Klana J, Nicolas-Chanoine MH: CTX-M-15-Producing *Escherichia coli* Clinical Isolates in Cairo (Egypt), Including Isolates of Clonal Complex ST10 and Clones ST131, ST73, and ST405 in Both Community and Hospital Settings. *Microb Drug Resist* 2011, 17(1): 67-73
 35. Feizabadi M, Etemadi G, Yadegarinia D, Rahmati M, Shabanpoor S, Bokaei : Antibiotic-resistance patterns and frequency of extended-spectrum β -lactamase-producing isolates of *Klebsiella pneumoniae* in Tehran. *Med Sci Monit* 2006, 12(1): BR362-365
 36. Mehrgan H, Rahbar M: Prevalence of extended-spectrum β -lactamase-producing *Escherichia coli* in a tertiary care hospital in Tehran, Iran. *Int J Antimicrob Agents* 2008, 31(2): 147-51
 37. Ramazanzadeh R, Chitsaz M, Bahmani N: Prevalence and Antimicrobial Susceptibility of Extended-Spectrum Beta-Lactamase-Producing Bacteria in Intensive Care Units of Sanandaj General Hospitals (Kurdistan, Iran). *Chemotherapy* 2009, 55(4): 287-292
 38. Feizabadi MM, Delfani S, Raji N, Majnooni A, Aligholi M, Shahcheraghi F, Parvin M, Yadegarinia D: Distribution of bla(TEM), bla(SHV), bla(CTX-M) genes among clinical isolates of *Klebsiella pneumoniae* at Labbafinejad Hospital, Tehran, Iran. *Microb Drug Resist* 2010, 16(1): 49-53
 39. Feizabadi MM, Mahamadi-Yeganeh S, Mirsalehian A, Mirafshar SM, Mahboobi M, Nili F, Yadegarinia D: Genetic characterization of ESBL-producing strains of *Klebsiella pneumoniae* from Tehran hospitals. *J Infect Dev Ctries* 2010, 4(10): 609-615.
 40. Hamidian M, Tajbakhsh M, Walther-Rasmussen J, Zali MR: Emergence of extended-spectrum β -lactamases in clinical isolates of *Salmonella enterica* in Tehran, Iran. *Jpn J Infect Dis* 2009, 62(5): 368-71
 41. Ranjbar R, Giammanco GM, Aleo A, Plano MR, Naghoni A, Owlia P, Mammina C: Characterization of the first extended-spectrum beta-lactamase-producing nontyphoidal *Salmonella* strains isolated in Tehran, Iran. *Foodborne Pathog Dis* 2010, 7(1): 91-95
 42. Al-Charrakh AH, Yousif SY, Al-Janabi H: Occurrence and detection of extended-spectrum β -lactamases in *Klebsiella* isolates in Hilla, Iraq. *African Journal of Biotechnology* 2011, 10(4): 657-665
 43. Poirel L, Fortineau N, Nordmann P: International Transfer of NDM-1-Producing *Klebsiella pneumoniae* from Iraq to France. *Antimicrob Agents Chemother* 2011, 55(4): 1821–1822
 44. Pfeifer Y, Matten J, Rabsch W: *Salmonella enterica* Serovar Typhi with CTX-M β -Lactamase, Germany. *Emerg Infect Dis* 2009, 15(9): 1533–1535
 45. Nicolas-Chanoine MH, Blanco J, Leflon-Guibout V, Demarty R, Alonso MP, Caniça MM, Park YJ, Lavigne JP, Pitout J, Johnson JR: Intercontinental emergence of *Escherichia coli* clone O25:H4-ST131 producing CTX-M-15. *J Antimicrob Chemother* 2008, 61(2): 273–281
 46. Coque TM, Novais Â, Carattoli A, Poirel L, Pitout J, Peixe L, Cantón R, Nordmann P: Dissemination of Clonally Related *Escherichia coli* Strains Expressing Extended-Spectrum β -Lactamase CTX-M-15. *Emerg Infect Dis* 2008, 14(2): 195-200
 47. Rotimi VO, Jamal W, Pal T, Sovenned A, Albert MJ: Emergence of CTX-M-15 type extended-spectrum β -lactamase-producing *Salmonella* spp. in Kuwait and the United Arab Emirates. *J Med Microbiol* 2008, 57(7): 881–886
 48. Al Sweih N, Salama MF, Jamal W, Al Hashem G, Rotimi VO: An outbreak of CTX-M-15-producing *Klebsiella pneumoniae* isolates in an intensive care unit of a teaching hospital in Kuwait. *Indian J Med Microbiol* 2011, 29(2): 130-135
 49. Dashti AA, Jadaon MM, Gomaa HH, Noronha B, Udo EE: Transmission of a *Klebsiella pneumoniae* clone harbouring genes for CTX-M-15-like and SHV-112 enzymes in a neonatal intensive care unit of a Kuwaiti hospital. *J Med Microbiol* 2010, 59(6): 687–692
 50. Al Hashem G, Al Sweih N, Jamal W, Rotimi VO: Sequence Analysis of blaCTX-M Genes Carried by Clinically Significant *Escherichia coli* Isolates in Kuwait Hospitals. *Med Princ Pract* 2010, 20(3): 213–219
 51. Kanj SS, Corkill JE, Kanafani ZA, Araj GF, Hart CA, Jaafar R, Matar GM: Molecular characterisation of extended spectrum β -lactamase-producing *Escherichia coli* and *Klebsiella* spp. isolates at a tertiary-care centre in Lebanon. *Eur J Clin Microbiol Infect Dis* 2008, 14(5): 501-504
 52. Matar GM, Jaafar R, Sabra A, Hart CA, Corkill JE, Dbaibo GS, Araj GF: First detection and sequence analysis of the bla-CTX-M-15 gene in Lebanese isolates of extended-spectrum- β -lactamase-producing *Shigella sonnei*. *Ann Trop Med Parasitol* 2007, 101(6): 511–517
 53. Moubarek C, Doucet-Populaire F, Hamze M, Daoud Z, Weill FX: First Extended-Spectrum- β -Lactamase (CTX-M-15)-Producing *Salmonella enterica* Serotype Typhimurium Isolate Identified in Lebanon. *Antimicrob Agents Chemother* 2005, 49(2): 864–865
 54. Matar GM, Kattar MM, Khairallah MT, Abi-Rached R, Mokhbat J: Detection of plasmid-encoded bla-CTX-M-15 and bla-TEM-1 genes in a Lebanese *Salmonella* isolate that produces extended-spectrum β -lactamase. *Ann Trop Med Parasitol* 2008, 102(7): 651–653
 55. Matar GM, Khairallah MT, Dandache I, Sabra A, Mokhbat J: Further evidence of plasmid-encoded bla-CTX-M-15 and bla-TEM-1 genes in Lebanese isolates of *Salmonella enterica* serovar Typhimurium that produce extended-spectrum β -lactamase. *Ann Trop Med Parasitol* 2010, 104(1): 91–94
 56. Rafay AM, Al-Muharrmi Z, Toki R: Prevalence of extended-spectrum beta-lactamases-producing isolates over a 1-year period at a University Hospital in Oman. *Saudi Med J* 2007, 28(1): 22-27
 57. Al Muharrmi Z, Rafay AM, Balkhair A, Al-Tamemi S, Al Mawali A, Al Sadiri H: Extended-spectrum β -lactamase (ESBL) in Omani Children: Study of prevalence, risk factors and clinical outcomes at Sultan Qaboos University Hospital, Sultanate of Oman. *Sultan Qaboos Univ Med J* 2008, 8(2): 171-177
 58. Al-Lawati AM, Crouch ND, Elhag KM: Antibiotic Consumption and Development of Resistance Among Gram-Negative Bacilli in Intensive Care Units In Oman. *Ann Saudi Med* 2000, 20(Nos 3-4): 324-327
 59. Al-Yaqoubi M, Elhag K: Susceptibilities of Common Bacterial Isolates from Oman to Old and New Antibiotics. *Oman Med J* 2008, 23(3)
 60. Poirel L, Al Maskari Z, Al Rashdi F, Bernabeu S, Nordmann P: NDM-1-producing *Klebsiella pneumoniae* isolated in the Sultanate of Oman. *The J Antimicrob Chemother* 2010, 66(2): 304-306

61. Al-Agamy MHM, Shibl AM, Tawfik AF: Prevalence and molecular characterization of extended-spectrum β -lactamase-producing *Klebsiella pneumoniae* in Riyadh, Saudi Arabia. *Ann Saudi Med* 2009, 29(4): 253–257
62. Bindayna K, Khanfar HS, Senok AC, Botta GA: Predominance of CTX-M genotype among extended spectrum β -lactamase isolates in a tertiary hospital in Saudi Arabia. *Saudi Med J* 2010, 30(8): 859–863
63. Tawfik AF, Alswailem AM, Shibl AM, Al-Agamy MH: Prevalence and genetic characteristics of TEM, SHV, and CTX-M in clinical *Klebsiella pneumoniae* isolates from Saudi Arabia. *Microb Drug Resist* 2011, 17(3): 383–388
64. Lartigue MF, Poirel L, Héritier C, Tolün V, Nordmann P: First description of CTX-M-15-producing *Klebsiella pneumoniae* in Turkey. *J Antimicrob Chemother* 2003, 52(2): 315–316
65. Yildirim I, Ceyhan M, Gur D, Mugnaioli C, Rossolini G: First Detection of VIM-1 Type Metallo- β -Lactamase in a Multidrug-Resistant *Klebsiella pneumoniae* Clinical Isolate from Turkey also Producing the CTX-M-15 Extended-Spectrum β -Lactamase. *J Chemother* 2007, 19(4): 467–468
66. Gonullu N, Aktas Z, Bal Kayacan C, Salcioglu M, Carattoli A, Yong DE, Walsh TR: Dissemination of CTX-M-15 β -Lactamase Genes Carried on Inc FI and FII Plasmids among Clinical Isolates of *Escherichia coli* in a University Hospital in Istanbul, Turkey. *J Clin Microbiol* 2008, 46(3): 1110–1112
67. Yumuk Z, Afacan G, Nicolas-Chanoine MH, Sotto A, Lavigne JP: Turkey: a further country concerned by community-acquired *Escherichia coli* clone O25-ST131 producing CTX-M-15. *J Antimicrob Chemother* 2008; 62(2): 284–288
68. Celik AD, Yulugkural Z, Kuloglu F, Eroglu C, Torol S, Vahaboğlu H, Akata F: CTX-M Type Extended Spectrum β -Lactamases in *Escherichia coli* Isolates From Community Acquired Upper Urinary Tract Infections at a University in the European Part of Turkey. *J Microbiol Immunol Infect* 2010, 43(2): 163–167
69. Azap O, Arslan H, Serefhanoglu K, Colakoglu S, Erdoğan H, Timurkaynak F, Senger SS: Risk factors for extended-spectrum β -lactamase positivity in uropathogenic *Escherichia coli* isolated from community-acquired urinary tract infections. *Eur J Clin Microbiol Infect Dis* 2010, 16(2): 147–151
70. Alfaresi MS, Elkoush AA, Alshehhi HM, Abdulsalam AI: Molecular Characterization and Epidemiology of Extended-Spectrum Beta-Lactamase-Producing *Escherichia coli* and *Klebsiella pneumoniae* Isolates in the United Arab Emirates. *Med Princ Pract* 2011, 20(2): 177–180
71. Astal Z, Sharif FA, Abdallah SA, Fahd MI: Extended spectrum β -lactamases in *Escherichia coli* isolated from community-acquired urinary tract infections in the Gaza Strip, Palestine. *Ann Saudi Med* 2004, 24(1): 55–57
72. Mubarak Bindayna K, Senok AC, Jamsheer AE: Prevalence of extended-spectrum β -lactamase-producing Enterobacteriaceae in Bahrain. *J Infect Public Health* 2009, 2(3): 129–135
73. Chmelnitsky I, Carmeli Y, Leavitt A, Schwaber MJ, Navon-Venezia S: CTX-M-2 and a New CTX-M-39 Enzyme Are the Major Extended-Spectrum β -Lactamases in Multiple *Escherichia coli* Clones Isolated in Tel Aviv, Israel. *Antimicrob Agents Chemother* 2005, 49(11): 4745–4750
74. Shehabi AA, Mahafzah A, Baadran I, Qadar FA, Dajani N: High incidence of *Klebsiella pneumoniae* clinical isolates to extended-spectrum β -lactam drugs in intensive care units. *Diagn Microbiol Infect Dis* 2000, 36(1):53–56
75. Khalaf NG, Eletreby MM, Hanson ND: Characterization of CTX-M ESBLs in *Enterobacter cloacae*, *Escherichia coli* and *Klebsiella pneumoniae* clinical isolates from Cairo, Egypt. *BMC Infect Dis* 2009, 9(84)
76. Paterson DL, Ko WC, Von Gottberg A, Casellas JM, Mulazimoglu L, Klugman KP, Bonomo RA, Rice LB, McCormack JG, Yu VL: Outcome of Cephalosporin Treatment for Serious Infections Due to Apparently Susceptible Organisms Producing Extended-Spectrum β -Lactamases: Implications for the Clinical Microbiology Laboratory. *J Clin Microbiol* 2001, 39(6): 2206–2212
77. Paterson DL, Yu VL: Extended spectrum β -lactamases: A Call for Improved Detection and Control. *Clin Infect Dis* 1999, 29(6):1419–1422

Publish with iMedPub

<http://www.imedpub.com>

- ✓ The Journal is an open access peer-reviewed journal that publishes scientific papers about all aspects of antimicrobials. The journal will publish original research articles, reviews, brief reports and case reports dealing with basic and clinical antibacterial agents, antiviral, antiprotazoals, antituberculous, antifungal and antihelminthes agents.
- ✓ All manuscripts must be prepared in English, and are subject to a rigorous and fair peer-review process. Accepted papers will immediately appear online.
- ✓ The journal aims to advance the knowledge, attitude and the research of chemotherapy in the Arabic world in cooperation with international, national scientific and public societies as well as research centers with similar aims and objectives.

Submit your manuscript here:

<http://www.iajaa.org>